Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.03 and traded as high as $0.03. Mateon Therapeutics shares last traded at $0.03, with a volume of 212,756 shares changing hands.
Mateon Therapeutics Trading Up 4.2 %
The business has a 50-day moving average price of $0.03 and a two-hundred day moving average price of $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Further Reading
- Five stocks we like better than Mateon Therapeutics
- What is the MACD Indicator and How to Use it in Your Trading
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- Upcoming IPO Stock Lockup Period, Explained
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- What Is WallStreetBets and What Stocks Are They Targeting?
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
